Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation (pages 3801–3811)
Jiansheng Wang, Jeannelyn S. Estrella, Lan Peng, Asif Rashid, Gauri R. Varadhachary, Hua Wang, Jeffrey E. Lee, Peter W. T. Pisters, Jean-Nicolas Vauthey, Matthew H. Katz, Henry F. Gomez, Douglas B. Evans, James L. Abbruzzese, Jason B. Fleming and Huamin Wang
Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26717
The authors demonstrate that histologic tumor involvement of the resected superior mesenteric vein (SMV)/portal vein (PV) is associated with larger tumor size, higher rates of positive margin, and local/distant recurrence, and is an independent predictor of both disease-free survival and overall survival by multivariate analysis. Complete histologic evaluation of the resected SMV/PV is important for the prognosis in patients with pancreatic adenocarcinoma treated with neoadjuvant therapy and pancreaticoduodenectomy.